Clinical Trial Update: KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating a KRAS-specific autologous TCR-T cell therapy for KRAS-mutant advanced solid tumors, including colorectal cancer, pancrea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• KRAS-specific autologous TCR-T cell therapy

Snippet

Sponsor: Corregene Biotechnology Co., Ltd | Conditions: Colorectal, Pancreatic | Phase 1 | Status: ACTIVE_NOT_RECRUITING